aml hub

Virtual AML Hub Satellite Symposium

EBMT | August 30, 2020 | 8:30 A.M. CEST

acute myeloid leukemia:

How does MRD impact outcome of stem cell transplantation in AML now and in the future?

During the virtual AML Hub Satellite Symposium, an international panel of five experts will discuss the advantages and challenges of using measurable residual disease (MRD) for prognosis and treatment decisions in patients with acute myeloid leukemia (AML) eligible for stem cell transplantation.

With the recent European LeukemiaNet Working Party guidelines, a standardized approach to MRD assessment in AML has become more feasible for clinical practice. The aim of this virtual symposium is to explore the benefits and limitations of current MRD assessments in order to make treatment teams familiar with MRD measurements in the context of stem cell transplantation.

5 experts
Join the conversation at the virtual 46th annual meeting of the EBMT
AUGUST 30, 2020 | 08:30 A.M. CEST


How does MRD impact outcome of stem cell transplantation in AML – now and in the future?

Sunday August 30, 2020 | 08:30 A.M. CEST

Welcome and introductions

Challenges in MRD measurement by multiparameter flow cytometry in AML

New developments in molecular MRD assessment in AML

Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?

Why should we use MRD assessment post hematopoietic stem cell transplantation?

Round table discussion and Q&A: Use of MRD-guided treatment decisions before and after transplantation

Summary and conclusions: Establishing MRD as a surrogate endpoint in AML, and what does the future hold?


Meeting concludes


Join the conversation – the virtual AML Hub Satellite Symposium will take place at the virtual 46th Annual Meeting of the EBMT.

icml banner

This site uses cookies in order for us to continually develop and improve the service we can offer you.Read more